Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227298 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

A Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
162
Enrollment target
5
Study locations

NCT07227298: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.

NCT07227298 is a Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Pfizer. The registered enrollment target is 162 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227298, a Phase 1 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
162 participants
Enrollment target
5
Study locations

Study Summary

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Primary Outcome

AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Conditions Studied

Non-Small Cell Lung Cancer Carcinoma, Non-Small Cell Lung Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions

  • BIOLOGICAL PF-08634404
  • BIOLOGICAL Sigvotatug Vedotin
  • BIOLOGICAL Combination Agent 1

Study Locations (5)

Other

  • Pan American Center for Oncology Trials, LLC - San Juan
  • BRCR Global Puerto Rico - Hato Rey - San Juan

Florida

  • Mid Florida Hematology and Oncology Center - Orange City

Oregon

  • Oncology Associates of Oregon, P.C - Eugene

Osaka

  • Kansai Medical University Hospital - Hirakata

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2026-01-30
Est. Completion 2033-08-23
Phase Phase 1
Pfizer

1,845 total trials

What NCT07227298 shows while recruiting

NCT07227298 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower).

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which PF-08634404 is the first listed.

NCT07227298 lists 5 locations in 4 states (Other, Florida, Oregon).

Frequently Asked Questions

What is clinical trial NCT07227298 about?

NCT07227298 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers". This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or...

What is the current status of trial NCT07227298?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2026-01-30. Estimated completion is 2033-08-23.

What conditions does trial NCT07227298 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Advanced/Metastatic Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT07227298?

The interventions under investigation include: PF-08634404 (BIOLOGICAL), Sigvotatug Vedotin (BIOLOGICAL), Combination Agent 1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07227298?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227298 being conducted?

This trial has 5 study locations across Florida, Oregon, Osaka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07227298's enrollment target sits among peer trials

162 189th of 454 higher than 264 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02347111 · 162 participants · Phase 4

    Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

  • NCT02610426 · 162 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  • NCT05040711 · 162 participants · NA

    mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

  • NCT05514717 · 162 participants · Phase 1

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07227298

Source: ClinicalTrials.gov NCT07227298, the US trial registry maintained by the National Library of Medicine. NCT07227298 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.